Dopamine and Motor Learning in Cerebral Palsy

Sponsor
National Institutes of Health Clinical Center (CC) (NIH)
Overall Status
Recruiting
CT.gov ID
NCT02839733
Collaborator
(none)
120
1
95
1.3

Study Details

Study Description

Brief Summary

Background:

Cerebral palsy (CP) is the most common childhood motor disability. The neurotransmitter dopamine (DA) is important in cognition and emotions/behavior. DA may also be important in motor skill learning. Genes that relate to DA function may affect a person s ability to learn new cognitive or motor skills. Some children with CP can learn motor skills easily while others have trouble. Researchers want to find out if DA gene variations cause some of this variability.

Objectives:

To learn more about how DA and its related genes affect motor and cognitive learning in people with and without CP.

Eligibility:
People ages 5 25 with and without CP who can:

Follow the protocol

Attend and perform the training sessions

Design:
Participants will be screened with:

Medical history

Physical exam

Blood draw for genetic tests

The study has 2 parts. Participants with CP can join both. Those without can join only Part 1.

All participants will have a baseline assessment: short motor skills test and blood draw.

Part 1:

Two 10-session training programs over 2 weeks. Cognitive training will be 2 sessions at the clinic, 8 at home. Participants will perform memory tasks on a computer. All 10 motor training sessions are at the clinic. Participants will step on lines in a virtual reality environment.

Part 2:

Two lab training sessions at least 1 week apart. Participants will perform tasks on a

computer.

Participants with CP may have a brain MRI at 1 visit. They will lie on a table that slides into a machine that takes pictures. They will be in the scanner about 45 minutes. They may have a

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Objective

    The broad objective of this study is to determine the relationship between variations in genes related to dopamine (DA) neurotransmission in areas of the brain associated with motor leaning (e.g. DRD1, DRD2, DRD3, COMT, DAT) and/or to activity-dependent brain plasticity (e.g. BDNF) and differences in motor learning rates and cognitive processing abilities in persons with and without cerebral palsy (CP). We hypothesize that individual genetic differences will be related to the ability to learn new motor and cognitive skills and may thus provide a potential explanation for the often reported response variability to rehabilitative therapies seen in CP. We will also explore whether motor and cognitive learning abilities are correlated within individuals which could suggest similar underlying neural mechanisms. Finally we would like to evaluate the effect of rewards on procedural learning in CP, to preliminarily assess how behavioral manipulations of the DA system may affect learning across individuals.

    Study Population: A maximum of 120 ambulatory children and young adults with and without CP (ages 5-25 inclusive) will be enrolled in this protocol.

    Design: This protocol will consist of two separate but related studies: Study #1 is an observational trial whereby subjects with and without CP will participate in two different training paradigms, 10 sessions each, one that involves learning novel working memory tasks and one that involves motor skill learning in the lower extremities, adapted from the horizontal ladder task utilized in rodent studies. All will have blood draws for genetic analyses at baseline, the results of which will be related to changes in performance (learning) per task after training.

    Study #2 will be a within-subjects evaluation in CP only on the effects of reward (versus no-reward) during learning, which is presumed to increase dopamine transmission. Mean and individual responses to reward-based learning will be assessed and related to genetic variations in dopamine transmission.

    For subjects with CP, we would like to obtain brain MRI but this is optional and if they are unable or unwilling to do this portion, they can still participate in this protocol.

    Outcome Measures: Primary outcomes are changes in performance (learning) on each task after training which will be related to presence or absence of polymorphisms that have been associated with brain plasticity or with deficits in working memory and/or motor learning. Individual responses to rewards will also be related to variations related to high versus low dopamine transmission in the brain.

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    120 participants
    Observational Model:
    Case-Control
    Time Perspective:
    Prospective
    Official Title:
    Dopamine and Motor Learning in Cerebral Palsy
    Actual Study Start Date :
    Jun 21, 2017
    Anticipated Primary Completion Date :
    May 22, 2025
    Anticipated Study Completion Date :
    May 22, 2025

    Arms and Interventions

    Arm Intervention/Treatment
    Cerebral Palsy

    Children and young adults with Cerebral Palsy.

    Healthy Volunteer

    Children and young adults healthy volunteer

    Outcome Measures

    Primary Outcome Measures

    1. Learning (specific measures vary by task) [measure of learning of each training task across the entire training period]

      There will be two tasks : 1 a motor task which involves walking across a horizontal ladder. 2. Computer base tasks targeting working memory and procedural learning

    2. Genetic testing (for dopamine and activity-related genes) [genetic analyses of individual variations]

      COMT, BDNF, DAT, and DRD1, DRD2, DRD3

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    5 Years to 25 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    • INCLUSION CRITERIA:
    For all subjects:
    1. Ages 5-25 inclusive

    2. Able to follow the study protocol

    3. Able to attend or perform the training sessions as scheduled

    Additional criteria for subjects with CP:
    1. Diagnosis of cerebral palsy

    2. Gross Motor Functional Classification Scale Level I-II (able to walk at least 10 meters without an assistive device)

    EXCLUSION CRITERIA:
    For all subjects:
    1. Presence of an injury or other medical condition (besides CP) that would affect motor function or the ability to perform the motor training program.
    Additional criteria for subjects with CP:
    1. Less than 6 months after major surgery to their legs

    2. Currently taking levodopa, trihexyphenidyl, methylphenidate or baclofen since these may affect dopamine transmission or neuroplasticity.

    Additional criteria for those with CP who choose to have an MRI:
    1. Have any of the following contraindications to having an MRI scan:

    2. Pregnancy

    3. A ventriculo-peritoneal shunt

    4. Have claustrophobia and not comfortable in small enclosed spaces

    5. Have metal that would make an MRI scan unsafe such as: cardiac pacemaker, insulin infusion pump, implanted drug infusion devise, cochlear or ear implant, transdermal medication patch (nitroglycerine), any metallic implants or objects, body piercing that cannot be removed, bone or joint pin, screw, nail, plate, wire sutures or surgical staples, shunts, cerebral aneurysms clips, shrapnel or other metal embedded (such as from war wounds or accidents or previous work in metal fields or machines that may have left any metallic fragments in or near your eyes).

    6. Excessive startle reaction to or fear of loud noises

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 National Institutes of Health Clinical Center Bethesda Maryland United States 20892

    Sponsors and Collaborators

    • National Institutes of Health Clinical Center (CC)

    Investigators

    • Principal Investigator: Diane L Damiano, Ph.D., National Institutes of Health Clinical Center (CC)

    Study Documents (Full-Text)

    None provided.

    More Information

    Additional Information:

    Publications

    Responsible Party:
    National Institutes of Health Clinical Center (CC)
    ClinicalTrials.gov Identifier:
    NCT02839733
    Other Study ID Numbers:
    • 160149
    • 16-CC-0149
    First Posted:
    Jul 21, 2016
    Last Update Posted:
    Jul 7, 2022
    Last Verified:
    Mar 11, 2022
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by National Institutes of Health Clinical Center (CC)
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jul 7, 2022